Exact Mass: 591.1360914

Exact Mass Matches: 591.1360914

Found 33 metabolites which its exact mass value is equals to given mass value 591.1360914, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

UDP-2-acetamido-2,6-dideoxy-beta-L-talose

UDP-2-acetamido-2,6-dideoxy-beta-L-talose; UDP-N-acetyl-beta-L-pneumosamine

C17H27N3O16P2 (591.0866522)

(E)-3-(6-Acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide

C30H27Cl2N5O4 (591.1440001999999)

muironolide A

C27H33Cl4NO5 (591.1112728)

Tetra-Ac-2-Phenylethyl glucosinolate

C23H29NO13S2 (591.1080264000001)

Fmoc-Glu(OtBu)-OPfp

C30H26F5NO6 (591.1680196)

BX-795

N-[3-[[5-Iodo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide

C23H26IN7O2S (591.0913366)

N-Desmethyl Prochlorperazine Dimaleate

C27H30ClN3O8S (591.144205)

Fiduxosin hydrochloride

C30H30ClN5O4S (591.170693)

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist

(E)-3-(6-Acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide

C30H27Cl2N5O4 (591.1440001999999)

D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D065168 - Bradykinin Receptor Antagonists D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

1-[2-[3-Carboxy-5-[[3-carboxy-3-(2-carboxy-2-hydroxy-5-oxopyrrolidin-1-yl)propyl]amino]-3-hydroxy-5-oxopentanoyl]oxyethyl]-2-hydroxy-5-oxopyrrolidine-2-carboxylic acid

C22H29N3O16 (591.1547754000001)

[(2S,3S,4R,5S,6S)-5-acetamido-3,4-dihydroxy-6-methyloxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate

C17H27N3O16P2 (591.0866522)

7-O-methylvitexin 2-O-beta-L-rhamnoside(1-)

C28H31O14- (591.1713726)

A flavonoid oxoanion obtained by deprotonation of the 5-hydroxy group of 7-O-methylvitexin 2-O-beta-L-rhamnoside. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).

2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1792526)

2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1792526)

2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1792526)

2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[4-(trifluoromethyl)phenyl]carbamoylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1792526)

2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[4-(trifluoromethyl)phenyl]carbamoylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1792526)

2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1792526)

2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1792526)

2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1792526)

Achromobactin free acid

C22H29N3O16 (591.1547754000001)

7-O-methylvitexin 2-O-alpha-L-rhamnoside(1-)

C28H31O14- (591.1713726)

GSK2033

C29H28F3NO5S2 (591.1360914)

GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.

24-ethyl-3,10,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-7-yl acetate

24-ethyl-3,10,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-7-yl acetate

C31H29NO11 (591.1740524)

1-{1-carboxy-3-[(3-carboxy-3-{2-[2-(2-carboxy-2-hydroxy-5-oxopyrrolidin-1-yl)ethoxy]-2-oxoethyl}-1,3-dihydroxypropylidene)amino]propyl}-2-hydroxy-5-oxopyrrolidine-2-carboxylic acid

C22H29N3O16 (591.1547754000001)

24-ethyl-3,7,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-10-yl acetate

24-ethyl-3,7,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-10-yl acetate

C31H29NO11 (591.1740524)

(17s)-24-ethyl-3,10,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-7-yl acetate

(17s)-24-ethyl-3,10,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-7-yl acetate

C31H29NO11 (591.1740524)

(17s)-24-ethyl-3,7,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-10-yl acetate

(17s)-24-ethyl-3,7,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-10-yl acetate

C31H29NO11 (591.1740524)